Abstract 380P
Background
Globally, there are roughly 476 million indigenous peoples in 90 nations worldwide, representing a wide range of cultures, dialects, and spirits. India has the world's second-highest concentration of tribal people after African countries. Spread across 705 tribes accounting for 8.6% of the country’s population, over 104 million tribal people live; making India home to numerous tribes with diverse origins, customs, and societal practices. Government of India have identified Primitive tribal communities on the basis of their pre-agricultural level of technology, extremely low level of literacy, and small, stagnant, or diminishing population. This epidemiological cross- sectional study was designed to assess the prevalence of oral cancer and its awareness among Irula tribes of South India.
Methods
A cross sectional descriptive study was conducted among 200 Irula tribes using a pretested Questionnaire, which included demographic information, tobacco habits, its frequency, and cancer awareness. Oral examination to assess oral cancer was done by a single examiner. SPSS version 21 was used to analyse the collected data.
Results
The findings revealed that 87% of the 200 study participants had no formal education and 38% had never visited a dentist. 64.5% practised indigenous brushing. There were 52% of oral mucosal lesions and 6% of malignant oral tumours found. This community had a very high prevalence of periodontal disease, tobacco chewing, and deeply ingrained beliefs and customs about dentition and dental treatment. The prevalence of oral mucosal lesions in the study population was due to tobacco use and a lack of knowledge about the harmful effects of the products used.
Conclusions
Although the problems associated with smoking and chewing tobacco are extensively documented in the literature, it is worrying that this indigenous group is not aware of the consequences. The public should be made aware of these concerns, especially those in high-risk groups, according to health specialists.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract
362P - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
Presenter: Irene Braña
Session: Poster Display
Resources:
Abstract
363P - Effect of financial distress and mental well-being of patients with early vs advanced oral cancer on informal caregiver's quality of life: A prospective real-world data from public health sector hospital
Presenter: Abhinav Thaduri
Session: Poster Display
Resources:
Abstract
364P - Artificial intelligence provides more accurately neck lymph nodes auto-segmentation in radiotherapy
Presenter: chiencheh Chen
Session: Poster Display
Resources:
Abstract
365P - Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis
Presenter: Anbarasan Anbazagan
Session: Poster Display
Resources:
Abstract
366P - Pre-treatment oral fungal microbiome and nasopharyngeal carcinoma prognosis: A population-based cohort study in southern China
Presenter: Yufeng Chen
Session: Poster Display
Resources:
Abstract
367P - Prevalence and association of sarcopenia with mortality in patients with head and neck cancer: A meta-analysis
Presenter: Claire Lim
Session: Poster Display
Resources:
Abstract
368P - Distinct gene expression profiling explored using nanostring tumor signalling 360 panel with validations in different clinical stages of oral submucous fibrosis patients: A first Indian study
Presenter: Yasasve Madhavan
Session: Poster Display
Resources:
Abstract
370P - Low-dose nivolumab with induction chemotherapy for inoperable HNSCC in 111 patients: Response rates, survival, and implications for LMICs
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
371P - The role of FDG-PET/CT in the assessment of response to radiation therapy in head and neck cancers: A systematic review and meta-analysis
Presenter: Felix Wijovi
Session: Poster Display
Resources:
Abstract